Market Overview

UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk

Share:

In a report published Friday, SunTrust Robinson Humphrey analyst Amit Hazan initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Reduce rating and $17.00 price target.

In the report, SunTrust Robinson Humphrey noted, “Our due diligence leads us to believe that the most imminent threat from new competitors for BRACAnalysis is not market share loss, but pricing pressures. We believe private insurer re-evaluation is currently ongoing on a broad scale and could realistically drive the price down by as much as 50% over the next two years. The Street's sales growth expectations for both FY14 and FY15 imply little to no pricing pressure, and we view that as a significant risk. The recent CMS reduction of COLARIS reimbursement by 46% is a good proxy here.”

Myriad Genetics closed on Thursday at $24.57.

Latest Ratings for MYGN

DateFirmActionFromTo
May 2020JP MorganMaintainsUnderweight
Apr 2020B of A SecuritiesReiteratesUnderperform
Mar 2020BarclaysMaintainsUnderweight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!

Posted-In: Amit Hazan SunTrust Robinson HumphreyAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
REGNCFRAMaintains549.0
NACFRAMaintains59.0
MRSNSVB LeerinkReiterates21.0
CTASB of A SecuritiesDowngrades
VICRBWS FinancialInitiates Coverage On84.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com